Zoledronic acid

Acute Tubular Necrosis — representative incidence ~17%.

Nephrotoxicity is the dose-limiting toxicity but largely avoidable; no precise population rate. Reported rate: renal toxicity in 17% — 852 patients with symptomatic newly diagnosed multiple myeloma and at least one lytic bone lesion who received at least… (Raje 2018, PMID 29429912).

Source: Raje et al., Lancet Oncol 2018

Reported injury signatures: Acute Tubular Necrosis, Fanconi Syndrome.

1. Acute Tubular NecrosisPrimary~9%Notable serum-creatinine rise (dose-defined) in ~9% of patients on IV zoledronic acid for bone metastases (range ~9-12% across retrospective renal-safety series); mechanism is toxic acute tubular necrosis
2. Fanconi SyndromeRareAcquired Fanconi syndrome in an AJKD case series and single-agent reports, resolving on withdrawal.

Acute (~1–7 days) — AKI days to weeks after an infusion.

• Rapid infusion
• High / frequent dosing
• Pre-existing CKD
• Volume depletion

• Slow infusion (≥15 min)
• Dose-adjust for CrCl
• Avoid if CrCl < 30–35

• Check serum creatinine before EVERY dose; withhold the next oncology dose until creatinine returns to within 10% of baseline (label-mandated)
• For myeloma/bone-metastasis dosing, document CrCl at baseline and select the renal-banded dose (4 mg only if CrCl >60 mL/min; 3.5/3.3/3.0 mg for CrCl 50-60/40-49/30-39); the hypercalcemia-of-malignancy dose is 4 mg unmodified
• Verify infusion time is at least 15 minutes and that the patient is volume-replete before each infusion
• Correct and monitor calcium, magnesium, phosphate and 25-OH vitamin D, repleting vitamin D/calcium to avoid hypocalcemia
• Screen urinalysis/spot protein for tubular proteinuria if creatinine rises, and review the med list for concurrent nephrotoxins (NSAIDs, contrast, aminoglycosides, loop diuretic-driven volume depletion)

• Major et al. pooled phase III analysis (J Clin Oncol 2001) — zoledronic acid 4-8 mg superior to pamidronate for hypercalcemia of malignancy; the 8 mg arm's excess renal deterioration drove adoption of the 4 mg/15-minute standard
• Rosen et al. myeloma/breast-cancer bone-metastasis trial (Cancer J 2001) — established 4 mg over 15 min q3-4wk and showed renal toxicity rises with higher dose and shorter infusion time
• HORIZON-PFT (Black et al., NEJM 2007) — once-yearly 5 mg in osteoporosis; transient post-dose creatinine rises mostly resolved, but informed the CrCl <35 mL/min contraindication for the osteoporosis dose
• Zometa Renal Safety / Saad et al. CRPC bone-metastasis trial (JNCI 2002) — confirmed creatinine-monitoring and dose-by-renal-function protocol after early grade renal events

• Nephrotoxicity is strongly driven by dose AND infusion rate—shortening below 15 minutes or giving 8 mg sharply raised renal events, which is why 4 mg over >=15 min is fixed
• Treat hypocalcemia and hypovitaminosis D proactively: pre-existing low calcium/vitamin D worsens post-infusion hypocalcemia and the metabolic picture
• Injury is often partially reversible if caught early by holding doses, but repeated dosing through a rising creatinine can produce persistent CKD
• In myeloma, weigh the bone benefit against the kidney: distinguishing drug ATN from cast nephropathy matters, and consider denosumab (no renal dosing, not renally cleared) when CrCl is low
• Zoledronate can cause acquired Fanconi syndrome / proximal tubular dysfunction (hypophosphatemia, glycosuria, aminoaciduria, acidosis) that resolves on withdrawal — a distinct lesion from its tubular necrosis.

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

• ASCO / CCO (2017) — Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline UpdateEndorses denosumab 120 mg SC q4w, pamidronate 90 mg IV q3-4w, or zoledronic acid 4 mg IV q12w or q3-4w; nitrogen bisphosphonates require renal function monitoring and dose/interval adjustment for impaired clearance, whereas denosumab needs no renal dose adjustment (with hypocalcemia risk in CKD).J Clin Oncol · PMID 29035643
• ADQI (2026) — The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupProvides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.Nat Rev Nephrol · PMID 41361704
• SIRM (2022) — SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.Radiol Med · PMID 35303246
• KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerIdentifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.Kidney Int · PMID 33126977
• KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationAddresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Kidney Int · PMID 33276867
• ADDIKD (2025) — Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceProvides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.EClinicalMedicine · PMID 40290844
• ADDIKD (2025) — Aligning kidney function assessment in patients with cancer to global practices in internal medicineThree consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.EClinicalMedicine · PMID 40290845
• ADDIKD (2025) — A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEstablishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.EClinicalMedicine · PMID 40290846
• KDIGO (2013) — Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.Crit Care · PMID 23394211
• KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsEvaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.Kidney Int · PMID 38519239
• KDIGO (2021) — Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesProvides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.Kidney Int · PMID 34556300
• KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisUpdates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.Kidney Int · PMID 38388147
• KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisUpdates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.Kidney Int · PMID 38182299
• KDIGO (2025) — Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.Kidney Int · PMID 40975525